Kazia Therapeutics (KZIA) is pleased to announce the regulatory approval and launch of a clinical trial evaluating the combination of paxalisib and immunotherapy in patients with advanced breast cancer. This novel treatment combination offers what is believed to be a unique approach to targeting this highly aggressive and treatment-resistant type of breast cancer. The ABC-Pax study is the first known trial conducted to assess the safety and efficacy of paxalisib in combination with KEYTRUDA or LYNPARZA in women with triple negative breast cancer. ABC-Pax is a multi-centre, open-label phase 1b study that will enroll 24 patients from top cancer centres in Queensland, Australia and patients will receive the combination therapy for up to 12 months.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KZIA:
- Kazia Therapeutics Issues Prefunded Warrant for ADS Purchase
- Kazia Therapeutics to sell 1.33M ADS at $1.50 in registered direct offering
- Kazia Therapeutics Charts Path Forward for Paxalisib After FDA Feedback
- Kazia announces FDA says OS data supports standard, not accelerated approval
- Kazia Therapeutics Presents Promising Data on Paxalisib for Breast Cancer Treatment